{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:57:14Z","timestamp":1793192234261,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc.","doi-asserted-by":"crossref","award":["Sarepta Therapeutics, Inc."],"award-info":[{"award-number":["Sarepta Therapeutics, Inc."]}],"id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Individuals with Duchenne muscular dystrophy (DMD) often require mobility aids and accessible homes and vehicles. Because these accommodations are not typically reimbursed by insurance, costs largely fall upon patients\u2019 families. Additionally, families often incur high out-of-pocket costs for DMD-related health services and treatments. Research describing these expenses is important to understand the full financial cost associated with DMD. The objective of this study was to quantify household costs associated with DMD-related accommodations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cross-sectional, retrospective online survey was conducted among United States-based family caregivers who provided informal (unpaid) care to \u2265\u20091 household member with DMD for \u2265\u200912 months and paid for \u2265\u20091 home\/vehicle-related expense in the past 5 years. Participants reported costs, external financial support, and affordability for (1) home\/vehicle purchases\/modifications, (2) non-reimbursed medical equipment, (3) non-reimbursed health services or drugs, and (4) other household expenses. Costs were averaged over all respondents and among those incurring costs (conditional means). Average costs were stratified by ambulatory status, upper-limb impairment, insurance coverage type, home ownership status, and annual combined household income.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 90 caregivers, 94.4% were female, 90.0% were White, and 82.1% were the primary caregiver. The mean (standard deviation [SD]) age of individuals with DMD (<jats:italic>n<\/jats:italic>\u2009=\u2009106) was 14.5 (5.3) years. Over half (59.4%) were reported as non-ambulatory, 23.6% as ambulatory, and 17.0% as transitioning from ambulatory to non-ambulatory. Average (SD) household costs over the past 5 years were $78,303 ($78,411) for home\/vehicle expenses and $14,071 ($27,427) for medical equipment. Major home\/vehicle expenses included purchasing\/modifying a handicap-accessible vehicle (64% in past 5 years; conditional mean 5-year cost: $47,997), modifying home entrances (61%; $16,750), and modifying bathrooms (46%; $13,512). Powered wheelchairs were the leading driver of medical equipment costs (43%; $15,718). Annual recurring, non-reimbursed health service and drug costs were $13,642 (SD $41,792). Other recurring annual household expenses were $2593 (SD $4144). Household costs generally increased with more advanced disease progression. Households were able to pay for some expenses using external funding from the US government (e.g., Medicaid waivers) and non-government resources (e.g., charitable foundations, independently raised funds). However, many caregivers reported having to forgo purchases due to prohibitive costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Households incur substantial costs to accommodate the functional impairments experienced by individuals with DMD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03794-1","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:52:55Z","timestamp":1749714775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver survey"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7274-3942","authenticated-orcid":false,"given":"Bryan","family":"Innis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Renteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"1","key":"3794_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3794_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3794_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and Gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3794_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo SM, Salhany RM, Deighton A, Harwood M, Mah J, Gooch KL. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021;16(1):237.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3794_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12955-022-02001-0","volume":"20","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Audhya IF, Rogula B, Feeny D, Gooch KL. Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI). Health Qual Life Outcomes. 2022;20(1):93.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3794_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/13696998.2022.2090152","volume":"25","author":"LL Freath","year":"2022","unstructured":"Freath LL, Curry AS, Cork DMW, Audhya IF, Gooch KL. QALYs and ambulatory status: societal preferences for healthcare decision making. J Med Econ. 2022;25(1):888\u201393.","journal-title":"J Med Econ"},{"issue":"5","key":"3794_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dmcn.12938","volume":"58","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, et al. Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol. 2016;58(5):508\u201315.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"3794_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.28075","volume":"70","author":"J Iff","year":"2024","unstructured":"Iff J, Done N, Tuttle E, Zhong Y, Wei F, Darras BT, et al. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle Nerve. 2024;70(1):60\u201370.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3794_CR9","doi-asserted-by":"publisher","first-page":"2216518","DOI":"10.1080\/20016689.2023.2216518","volume":"11","author":"AC Klimchak","year":"2023","unstructured":"Klimchak AC, Sedita LE, Rodino-Klapac LR, Mendell JR, McDonald CM, Gooch KL, et al. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. J Mark Access Health Policy. 2023;11(1):2216518.","journal-title":"J Mark Access Health Policy"},{"issue":"8","key":"3794_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/0883073808314962","volume":"23","author":"L Ouyang","year":"2008","unstructured":"Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol. 2008;23(8):883\u20138.","journal-title":"J Child Neurol"},{"issue":"6","key":"3794_CR11","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3794_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"issue":"3","key":"3794_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mus.23942","volume":"49","author":"J Larkindale","year":"2014","unstructured":"Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431\u20138.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3794_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3794_CR15","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39(6):2906\u201319.","journal-title":"Adv Ther"},{"issue":"6","key":"3794_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3233\/JND-220816","volume":"9","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Klimchak AC, Qian C, Iannaccone S, Popoff E, Gooch KL. Characterizing the occurrence of key clinical milestones in Duchenne muscular dystrophy in the United States using real-World data. J Neuromuscul Dis. 2022;9(6):689\u201399.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"3794_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0883073811420719","volume":"27","author":"L Ouyang","year":"2012","unstructured":"Ouyang L, Grosse SD, Fox MH, Bolen J. A National profile of health care and family impacts of children with muscular dystrophy and special health care needs in the united States. J Child Neurol. 2012;27(5):569\u201376.","journal-title":"J Child Neurol"},{"issue":"5","key":"3794_CR18","first-page":"e39597","volume":"15","author":"A Balidemaj","year":"2023","unstructured":"Balidemaj A, Parsamanesh P, Vysochyn M. Exploring the dynamics of caring for a child with a terminal illness of Duchenne muscular dystrophy (DMD) and its copious components on the caregivers. Cureus. 2023;15(5):e39597.","journal-title":"Cureus"},{"issue":"1","key":"3794_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s41687-021-00386-y","volume":"5","author":"CE Schwartz","year":"2021","unstructured":"Schwartz CE, Stark RB, Audhya IF, Gooch KL. Characterizing the quality-of-life impact of Duchenne muscular dystrophy on caregivers: a case-control investigation. J Patient Rep Outcomes. 2021;5(1):124.","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"3794_CR20","first-page":"212","volume":"8","author":"D Porteous","year":"2021","unstructured":"Porteous D, Davies B, English C, Atkinson J. An integrative review exploring psycho-social impacts and therapeutic interventions for parent caregivers of young people living with Duchenne\u2019s muscular dystrophy. Children (Basel). 2021;8(3):212.","journal-title":"Child (Basel)"},{"issue":"10","key":"3794_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","volume":"60","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Edstrom J, Buccella F, Kirschner J, Lochmuller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987\u201396.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"3794_CR22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","volume":"263","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, et al. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol. 2016;263(5):906\u201315.","journal-title":"J Neurol"},{"issue":"6","key":"3794_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.27429","volume":"64","author":"RH Soelaeman","year":"2021","unstructured":"Soelaeman RH, Smith MG, Sahay K, Tilford JM, Goodenough D, Paramsothy P, et al. Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies. Muscle Nerve. 2021;64(6):717\u201325.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"e20161287","DOI":"10.1542\/peds.2016-1287","volume":"139","author":"JA Romley","year":"2017","unstructured":"Romley JA, Shah AK, Chung PJ, Elliott MN, Vestal KD, Schuster MA. Family-provided health care for children with special health care needs. Pediatrics. 2017;139(1):e20161287.","journal-title":"Pediatrics"},{"key":"3794_CR25","unstructured":"The Lewin Group. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States. 2012 Mar 1 [cited 29 Jul 2024]. Available from: https:\/\/www.mda.org\/sites\/default\/files\/Cost_Illness_Report_0.pdf"},{"key":"3794_CR26","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.2147\/JMDH.S458181","volume":"17","author":"R Fischer","year":"2024","unstructured":"Fischer R, Furlong P, Kennedy A, Maynard K, Penrod M, Miller D, et al. Healthcare stakeholder perspectives on a value assessment approach for Duchenne muscular dystrophy therapies. J Multidiscip Healthc. 2024;17:4199\u2013212.","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"3794_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","volume":"17","author":"G Yang","year":"2022","unstructured":"Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The National economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3794_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41687-022-00425-2","volume":"6","author":"CE Schwartz","year":"2022","unstructured":"Schwartz CE, Stark RB, Borowiec K, Audhya IF, Gooch KL. Interplay of disability, caregiver impact, and out-of-pocket expenditures in Duchenne muscular dystrophy: a cohort study. J Patient Rep Outcomes. 2022;6(1):21.","journal-title":"J Patient Rep Outcomes"},{"issue":"7","key":"3794_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: asystematic review of cost of illness evidence. Health Policy. 2015;119(7):964\u201379.","journal-title":"Health Policy"},{"key":"3794_CR30","unstructured":"U.S. Census Bureau. QuickFacts: United States. Population Estimates, July 1, 2024 (V2024). [cited March 21, 2025]. Available from: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US#"},{"key":"3794_CR31","unstructured":"Census.gov: U.S. Bureau of Labor Statistics and U.S. Census Bureau. Table 1. Educational Attainment of the Population 18 Years and Over, by Age, Sex, Race, and Hispanic Origin: 2022. [cited March 21, 2025]. Available from: https:\/\/www.census.gov\/data\/tables\/2022\/demo\/educational-attainment\/cps-detailed-tables.html"},{"key":"3794_CR32","unstructured":"Census.gov: U.S. Bureau of Labor Statistics and U.S. Census Bureau. Income in 2023. [cited March 21, 2025]. Available from: https:\/\/www.census.gov\/library\/publications\/2024\/demo\/p60-282.html"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03794-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:53:02Z","timestamp":1749714782000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03794-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03794-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This non-interventional study was exempted from institutional review by WCG Institutional Review Board. Informed consent was obtained from all caregivers prior to initiation of the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BI and IA are employees of Sarepta Therapeutics, Inc., and may hold stock or stock options. JJ and TR are employed by Medicus Economics, which received consulting fees from Sarepta Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}